New hope for liver cancer: targeted chemo shows promise
NCT ID NCT02028949
First seen Feb 15, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This early-phase study tested a new way to deliver a chemotherapy drug (idarubicin) directly to liver tumors in 15 people with advanced liver cancer that could not be surgically removed. The drug was mixed with a special oil (lipiodol) and injected into the liver artery to concentrate the treatment on the tumor while reducing side effects. The main goal was to find a safe dose and check for toxicity, with additional monitoring of survival and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE NON-METASTATIC HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Dijon
Dijon, 21079 Cedex, France
Conditions
Explore the condition pages connected to this study.